AEM-28-14

N/A

Report date: 2025/10/28 17:00:23
NME

Base Information

Drug NameAEM-28-14
Drug Alias NameAEM-28 analog (LipimetiX Development/Anji Pharma)chimeric Apo E mimetic peptide (LipimetiX Development/Anji Pharma)AEM-28-14
ClassificationSmall molecules > Peptidomimetic
Mechanisms of ActionApolipoprotein E agonists
TargetsApolipoprotein E
Therapy Area/IndicationsHomozygous familial hypercholesterolemiaHypertriglyceridemiaHyperlipidemias +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanHong Kong +[4] 
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPending
Originator CompaniesCapstone Therapeutics Corp
China Registration ClassN/A

Develop Information

Active CompaniesCapstone Therapeutics CorpLipimetix Development Llc
Inactive CompaniesAnji PharmaceuticalsUniversity Of Alabama At Birmingham
Active IndicationsHomozygous familial hypercholesterolemia
Inactive IndicationsHypertriglyceridemiaHyperlipidemiasHyperlipoproteinemia Type II +[5] 

Other Information

ATC CodeN/A
Related LinksN/A